Statement of Ownership (sc 13g)

Date : 02/14/2020 @ 2:27PM
Source : Edgar (US Regulatory)
Stock : Viveve Medical Inc (VIVE)
Quote : 0.689  0.0539 (8.49%) @ 1:00AM
Viveve Medical share price Chart
After Hours
Last Trade
Last $ 0.68 ▼ -0.01 (-1.31%)

Statement of Ownership (sc 13g)


| OMB APPROVAL |
|_____________________|
|OMB NUMBER: |
UNITED STATES |EXPIRES: |
SECURITIES AND EXCHANGE COMMISSION | JUNE 30, 2012 |
Washington, D.C. 20549 |ESTIMATED AVERAGE |
|BURDEN HOURS |
|PER RESPONSE ...11 |
SCHEDULE 13G _____________________|

Under the Securities Exchange Act of 1934
(Amendment No. _ )*

Viveve Medical Inc (VIVE)
(Name of Issuer)

Common Stock
(Title of Class of Securities)

92852W303
(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

[X] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[ ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------------------------------------------------------------------------------
CUSIP No.  92852W303                    SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Investment Group, L.P.

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF                               0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                244,811
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
                                        0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        244,811
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          244,811
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           6.1%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           IA
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 244,811 shares of Common
Stock of the Issuer, which constitute approximately 6.1% of the Issuer's
outstanding Common Stock shares. The percentage calculation assumes that there
are currently 4,023,472 outstanding shares of Common Stock of the Issuer,
based on the Issuer's 8K, as filed with the Securities and Exchange Commission
on November 27, 2019.

------------------------------------------------------------------------------
CUSIP No.  92852W303                    SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Fund GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF                               0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                244,811
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
                                        0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        244,811
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          244,811
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           6.1%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           OO
------------------------------------------------------------------------------
 *The reporting persons are the beneficial owners of 244,811 shares of Common
Stock of the Issuer, which constitute approximately 6.1% of the Issuer's
outstanding Common Stock shares. The percentage calculation assumes that there
are currently 4,023,472 outstanding shares of Common Stock of the Issuer,
based on the Issuer's 8K, as filed with the Securities and Exchange Commission
on November 27, 2019.

------------------------------------------------------------------------------
CUSIP No.  92852W303                    SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Fund 2 GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF                               0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                244,811
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
                                        0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        244,811
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          244,811
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           6.1%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           OO
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 244,811 shares of Common
Stock of the Issuer, which constitute approximately 6.1% of the Issuer's
outstanding Common Stock shares. The percentage calculation assumes that there
are currently 4,023,472 outstanding shares of Common Stock of the Issuer,
based on the Issuer's 8K, as filed with the Securities and Exchange Commission
on November 27, 2019.

------------------------------------------------------------------------------
CUSIP No.  92852W303                    SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Fund 3 GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF                               0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                244,811
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
                                        0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        244,811
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          244,811
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           6.1%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           OO
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 244,811 shares of Common
Stock of the Issuer, which constitute approximately 6.1% of the Issuer's
outstanding Common Stock shares. The percentage calculation assumes that there
are currently 4,023,472 outstanding shares of Common Stock of the Issuer,
based on the Issuer's 8K, as filed with the Securities and Exchange Commission
on November 27, 2019.
-------------------------------------------------------------------------------
CUSIP No. 92852W303              SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
          Anand Parekh

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions):
                                                           (a) [ ]
                                                           (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
          United States of America
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF                               0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                244,811
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
                                        0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        244,811
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          244,811
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
          6.1%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
          IN
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 244,811 shares of Common
Stock of the Issuer, which constitute approximately 6.1% of the Issuer's
outstanding Common Stock shares. The percentage calculation assumes that there
are currently 4,023,472 outstanding shares of Common Stock of the Issuer,
based on the Issuer's 8K, as filed with the Securities and Exchange Commission
on November 27, 2019.



CUSIP NO.  92852W303             SCHEDULE 13G


Item 1(a).      Name of Issuer:
                Viveve Medical, Inc.



Item 1(b).      Address of Issuer's Principal Executive Offices:
                345 Inverness Drive South, Building B, Suite 250
                Englewood, Colorado 80112



Item 2(a).      Name of Persons Filing:

        (i)     Alyeska Investment Group, L.P.

        (ii)    Alyeska Fund GP, LLC

        (iii)   Alyeska Fund 2 GP, LLC

        (iv)    Alyeska Fund 3 GP, LLC

        (v)     Anand Parekh




Item 2(b).      Address of Principal Business Office or, if None, Residence:


        (i)     77 West Wacker Drive, 7th Floor
                Chicago, IL 60601

        (ii)    77 West Wacker Drive, 7th Floor
                Chicago, IL 60601

        (iii)   77 West Wacker Drive, 7th Floor
                Chicago, IL 60601

        (iv)    77 West Wacker Drive, 7th Floor
                Chicago, IL 60601

        (v)     77 West Wacker Drive, 7th Floor
                Chicago, IL 60601


Item 2(c).      Citizenship:

                (i)     Alyeska Investment Group, L.P.- Delaware

                (ii)    Alyeska Fund GP, LLC- Delaware

                (iii)   Alyeska Fund 2 GP, LLC- Delaware

                (iv)    Alyeska Fund 3 GP, LLC- Delaware

                (v)     Anand Parekh - United States of America





Item 2(d).       Title of Class of Securities:
                 Common Stock


Item 2(e).      CUSIP Number:
                92852W303



Item 3.          If This Statement is Filed Pursuant to Sections 240.13d-1(b)
                 or 240.13d-2(b), Check Whether the Person Filing is a:

(a) Alyeska Investment Group, L.P., a limited partnership organized under the
laws of the State of Delaware, is a registered investment adviser under Section
203 of the Investment Advisers Act of 1940, as amended, and is reporting in
accordance with 240.13d-1(b)(1)(ii)(E).

(b) Alyeska Fund GP, LLC, a limited liability company organized under the laws
of the State of Delaware, serves as the General Partner and control person of
Alyeska Master Fund, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).

(c) Alyeska Fund 2 GP, LLC, a limited liability company organized under the laws
 of the State of Delaware, serves as the General Partner and control person of
Alyeska Master Fund 2, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).

(d) Alyeska Fund 3 GP, LLC, a limited liability company organized under the laws
 of the State of Delaware, serves as the General Partner and control person of
Alyeska Master Fund 3, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).

(e) Anand Parekh is the Chief Executive Officer and control person of Alyeska
Investment Group, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).



Item 4.  Ownership.

Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer identified
in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover
        pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached
        hereto

    (c) Number of shares as to which the person has: Please refer to items
        5-8 of the cover pages attached hereto

The reporting persons are the beneficial owners of (i) 81,811 shares of
Common Stock of the Issuer, and (ii) warrants to purchase 163,000 shares of
the Issuer's Common Stock (the "Warrants"). Per their terms, the Warrants can
only be exercised into such number of shares that would constitute 9.99% of the
total number of Common Stock of the Issuer outstanding immediately after giving
effect to the issuance of shares of Common Stock upon exercise of the Warrants
by the Holder. Accordingly, as of December 31, 2019, the reporting persons may
exercise all 163,000 shares of Common Stock under the Warrants, and as such, are
reporting beneficial ownership of 244,811 shares. The percentage calculation
assumes that there are currently 4,023,472 outstanding shares of Common Stock
of the Issuer, based on the Issuer's 8K, as filed with the Securities and
Exchange Commission on November 27, 2019.


Item 5.  Ownership of Five Percent or Less of a Class.
         Not Applicable



Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
         Not Applicable



Item 7.  Identification and Classification of the Subsidiary Which Acquired
         the Security Being Reported on By the Parent Holding Company or
         Controlling Person.
         Not Applicable



Item 8.  Identification and Classification of Members of the Group.
         Not Applicable


Item 9.  Notice of Dissolution of Group
         Not Applicable



Item 10. Certification

        By signing below I certify that, to the best of my knowledge and
        belief, the securities referred to above were not acquired and
        are not held for the purpose of or with the effect of changing or
        influencing the control of the issuer of the securities and were
        not acquired and are not held in connection with or as a participant
        in any transaction having that purpose or effect, other than
        activities solely in connection with a nomination under ? 240.14a-11.


CUSIP NO.  92852W303              SCHEDULE 13G


                                   SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.


Dated: February 14, 2020


Alyeska Investment Group, L.P.

By: /s/ Jason Bragg
    -------------------------------
    Name: Jason Bragg
    Title: Chief Financial Officer


Alyeska Fund GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Alyeska Fund 2 GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Alyeska Fund 3 GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Anand Parekh

By: /s/ Anand Parekh
    -------------------------------
    Name: Anand Parekh
    Individually




CUSIP NO. 92852W303             SCHEDULE 13G


                                Exhibit A
                                Agreement


The undersigned agree that the statement to which this exhibit is appended is
filed on behalf of each of them.

Dated:  February 14, 2020


Alyeska Investment Group, L.P.

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Alyeska Fund GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Alyeska Fund 2 GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Alyeska Fund 3 GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer


Anand Parekh

By: /s/ Anand Parekh
    -------------------------------
    Name: Anand Parekh
    Individually

Viveve Medical (NASDAQ:VIVE)
Historical Stock Chart

1 Year : From Mar 2019 to Mar 2020

Click Here for more Viveve Medical Charts.

Viveve Medical (NASDAQ:VIVE)
Intraday Stock Chart

Today : Tuesday 31 March 2020

Click Here for more Viveve Medical Charts.

Latest VIVE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
$
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200401 02:02:06